GridAI Technologies Corp.

GridAI Technologies Corp. and its subsidiaries design and develop an AI-driven software and device platform that helps utilities, retailers, and large power users manage load and distributed energy resources. The company is also developing Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. It is based in Edinburgh, United Kingdom.